Tag: BRCA

Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Continue Reading Characterization of Blood- Based Molecular Profiling in Pancreatic Adenocarcinoma

BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

An analysis of germline-somatic interactions in breast cancer tumors revealed novel associations relevant to the disease’s progression and treatment resistance. For example, the study presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) showed that carriers of the BRCA2 mutation had inferior outcomes to treatment with first-line CDK4/6 inhibitors…

Continue Reading BRCA2 Linked to Inferior Outcomes of Treatment With CDK4/6 Inhibitors Plus Endocrine Therapy

The Evolving Treatment Landscape of Cholangiocarcinoma

Recent genomic profiling studies revealed that approximately 40% of patients with biliary tract cancers harbor actionable genomic mutations. The advances in the understanding and characterization of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), and genomic profiling over the past decade have led to a rapid expansion of available treatment…

Continue Reading The Evolving Treatment Landscape of Cholangiocarcinoma

Index of /runs/gdc/report_2018_02_16

Name Last modified Size Description Parent Directory   –   TCGA-ACC.2018_02_16.diced_metadata.tsv 2018-02-16 01:06 250K   TCGA-ACC.2018_02_16.high_res.heatmap.png 2018-02-16 01:08 73K   TCGA-ACC.2018_02_16.low_res.heatmap.png 2018-02-16 01:08 37K   TCGA-ACC.2018_02_16.sample_counts.tsv 2018-02-16 01:06 142   TCGA-BLCA.2018_02_16.diced_metadata.tsv 2018-02-16 01:06 1.2M   TCGA-BLCA.2018_02_16.high_res.heatmap.png 2018-02-16 01:08 90K   TCGA-BLCA.2018_02_16.low_res.heatmap.png 2018-02-16 01:08 53K   TCGA-BLCA.2018_02_16.sample_counts.tsv 2018-02-16 01:06 201  …

Continue Reading Index of /runs/gdc/report_2018_02_16

r – ggplot: Try to plot boxplots with geom_rect on its background, but keep having error with object “variable” not found

I was almost desperate with this error after working on this for 4 hrs, googled and looked from past posts already. Here is my data structure: str(tcga_exp) ‘data.frame’: 11775 obs. of 5 variables: $ cohort: chr “BRCA-Basal.Tumor” “BRCA-LumA.Tumor” “BRCA-LumB.Tumor” “BRCA-LumA.Tumor” … $ exp : num 6.35 5.54 6.56 5.05 5.98…

Continue Reading r – ggplot: Try to plot boxplots with geom_rect on its background, but keep having error with object “variable” not found

Identification of lipid metabolism-associated gene signature

Background Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer. Despite the dramatic improvement in breast cancer prognosis due to recent therapeutic advances, such as more effective adjuvant and neo-adjuvant chemotherapies, together with more radical and safer surgery, advances in early diagnosis and treatment over the…

Continue Reading Identification of lipid metabolism-associated gene signature

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

Getting exon sequences for all human genes

Getting exon sequences for all human genes 2 Hi everyone, I would be very grateful if you could help me. I want to download the sequences of all the exons for each human gene. I went to ensembl biomart and tried to do it for BRCA2 first (this was a…

Continue Reading Getting exon sequences for all human genes

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

High tumor mutation burden and DNA repair gene mutations

Introduction Anaplastic lymphoma kinase (ALK)‑fusion genes represent a small but important part of oncogenic driver mutations in NSCLC, accounting for approximately 3%‑7% of all cases worldwide.1,2 Small molecule tyrosine kinase inhibitors (TKIs) are the standard therapy for ALK-rearranged NSCLC. Crizotinib, a first-generation TKI, is the most widely used targeted drug…

Continue Reading High tumor mutation burden and DNA repair gene mutations

Personalized profiles for disease risk must capture all facets of health

Providing the best possible care for an individual means having a better understanding of their risks of developing disease. The goal is to have personalized answers when people need to know whether, for instance, preventive surgery makes sense, a given medicine is likely to be risky or a certain diet…

Continue Reading Personalized profiles for disease risk must capture all facets of health

Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome

This article was originally published here Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446. doi: 10.1016/j.csbj.2021.08.007. eCollection 2021. ABSTRACT Poly (ADPribose) polymerase inhibitors (PARPis) are clinically approved drugs designed according to the concept of synthetic lethality (SL) interaction. It is crucial to expand the scale of patients who can benefit from…

Continue Reading Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome

Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors

Abstract The metabolic mechanisms involved in the survival of tumor cells within the hypoxic niche remain unclear. We carried out a synthetic lethal CRISPR screen to identify survival mechanisms governed by the tumor hypoxia–induced pH regulator carbonic anhydrase IX (CAIX). We identified a redox homeostasis network containing the iron-sulfur cluster…

Continue Reading Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors

pughlab/inspire-genomics: Pan-cancer analysis of genomic and immune landscape profiles of metastatic solid tumors treated with pembrolizumab

Contents Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist to show the relationship between ctDNA dynamics and tumor genome and immune microenvironment in patients receiving ICB. Here, we present…

Continue Reading pughlab/inspire-genomics: Pan-cancer analysis of genomic and immune landscape profiles of metastatic solid tumors treated with pembrolizumab

Predicting and characterizing a cancer dependency map of tumors with deep learning

INTRODUCTION The development of novel cancer therapies requires knowledge of specific biological pathways to target individual tumors and eradicate cancer cells. Toward this goal, the landscape of genetic vulnerabilities of cancer, or the cancer dependency map, is being systematically profiled. Using RNA interference (RNAi) loss-of-function screens, Marcotte et al. (1),…

Continue Reading Predicting and characterizing a cancer dependency map of tumors with deep learning

Overall survival and Event free survival

Overall survival and Event free survival 0 Hello everyone. I have a simple question. How do I calculate the overall survival (OS) rate and Event-free survival (EFS) using TCGA-BRCA clinical data? which column must be used for each one? Also, can I use the first quartile as my risk score…

Continue Reading Overall survival and Event free survival

Differential expression analysis of TCGA data based on tumor staging

Hi everyone I wanted to analyze TCGA-BRCA data for identifying DEGs in different TNM stages (I to IV) between Normal and Tumor. How to change the following code to get the DEGs based on the staging? CancerProject <- “TCGA-BRCA” DataDirectory <- paste0(“../GDC/”,gsub(“-“,”_”,CancerProject)) FileNameData <- paste0(DataDirectory, “_”,”HTSeq_Counts”,”.rda”) query <- GDCquery(project =…

Continue Reading Differential expression analysis of TCGA data based on tumor staging

Survival Analysis Cut-off

Survival Analysis Cut-off 0 Hello guys, I am doing a survival analysis using TCGA-BRCA project data. I am trying different cut-offs to separate my samples into high and low risk groups, but since it is my first time I would like to ask a question just to be fully sure…

Continue Reading Survival Analysis Cut-off